Even among cancers, pancreatic cancer is an especially sinister form of disease. The one-year survival rate is extremely low, and treatment progress has lagged behind that of many other malignancies.
A study published today in the journal Nature Medicine led by researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) describes a new therapeutic approach with potential for patients with pancreatic cancer. These researchers discovered a combination drug therapy that may effectively combat the disease. HCI researchers first observed anti-cancer impacts in a laboratory setting and, subsequently, in its first use in a human patient.
The study has already progressed to a clinical trial that is now open at HCI and will soon be open at other sites in the United States. Details about the clinical trial, called THREAD, are available under National Clinical Trial Number 03825289. The combination therapy uses two drugs already approved for use by the Food and Drug Administration for other diseases, including cancer. The new drug combination is administered through pills taken orally.
Pancreatic tumors are characterized by mutations in a gene called KRAS. When KRAS is mutated in this way, it sends constant signals that promote abnormal cell division and growth in cancer cells. As a result, tumors grow out of control. At the same time, like all cells, pancreatic cancer cells must recycle their components to provide building blocks for new growth in an essential cell function known as autophagy. Previous studies to combat pancreatic cancer that were focused either on the role of KRAS or on impacting autophagy were not effective.
The new HCI study, using an approach that simultaneously targets both abnormal KRAS signaling and the autophagy process, shows a strong response in mouse models and may be a promising therapy for patients with pancreatic cancer. Conan Kinsey, MD, PhD, a physician-scientist at Huntsman Cancer Institute and the Department of Internal Medicine at the U of U and Martin McMahon, PhD, a cancer researcher at HCI and Professor of Dermatology at the U of U, led the study.
“We were able to observe that the combination of these two drugs – which, when used individually, don’t have much of an impact on the disease – appears to have a very potent impact on the growth of pancreatic cancer,” says McMahon. “We have observed this in the lab in petri dishes, then in mouse models, and now in a pancreatic cancer patient on a compassionate use basis. Indeed, we proceeded from a petri dish to a patient in less than two years – a timeline that is rarely seen in medical science.”
The HCI-led research is bolstered by a separate study published in the same issue of the journal. This study outlines complementary findings regarding the effects of autophagy in pancreatic cancer in the laboratory setting and was led by Channing Der, PhD, Sarah Graham Kenan, PhD, and Kirsten Bryant, PhD, at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center. McMahon and Der learned about the parallel nature of their research programs at a scientific meeting one year ago. Given the critical need for advances in pancreatic cancer therapies and the promise of their collective findings, they worked together to push their studies forward on a companion basis.
“In our paper, we show the response of a pancreatic cancer patient who had received surgery and multiple lines of chemotherapy prior to this combination,” said Kinsey, who was also the patient’s physician. “This patient, who has since succumbed to the disease, nevertheless had a remarkable response to these drugs for several months. We need to carefully evaluate this new combination therapy in the context of clinical trials to better understand if good responses might be seen in multiple patients. We also need to identify the specific features of any patient who may benefit, before any recommendation can be made about use on a larger scale.”
These preliminary findings are being rigorously scrutinized in clinical trials to observe and understand whether the combination of these drugs is safe and effective for pancreatic cancer patients. The trial is underway at HCI and is underway or planned at the University of California, San Francisco, and Columbia University in New York.
“In publishing how this new approach of mixing two medicines typically associated with malaria and melanoma can treat pancreatic tumors with KRAS mutations, we are hoping the clinical trial supported by the Pancreatic Cancer Collective’s New Therapies Challenge Grant will help us learn how to best administer these medicines, so that we can maximize the benefit for as many patients as possible,” said David Tuveson, MD, PhD, Lustgarten’s Chief Scientist, Director of the Cancer Center at Cold Spring Harbor Laboratory, Co-Scientific Leader of the Collective.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- ‘ICU grandpa’ who cradled babies dies from pancreatic canceron November 22, 2020 at 9:59 am
David Deutchman spent most of his free time volunteering at Children's Healthcare of Atlanta and cradled babies in the neonatal intensive care unit. For nearly 15 years, he was known as the "ICU ...
- 'ICU grandpa' who won hearts by snuggling babies dies from pancreatic canceron November 21, 2020 at 9:00 am
“Volunteering absolutely enriched his life,” his daughter said. “It brought us great pleasure to see him having that impact." ...
- Alex Trebek raises awareness of ‘terrible’ pancreatic cancer in pre-recorded ‘Jeopardy!’ videoon November 20, 2020 at 3:39 pm
During the beginning of Thursday’s episode of “Jeopardy!”, the late veteran TV personality shared a pre-taped message on the day dedicated to raising awareness and funds for pancreatic cancer.
- Alex Trebek’s Widow Jean Marks World Pancreatic Cancer Day In Her Late Husband’s Memoryon November 20, 2020 at 12:37 pm
Many fans of Jeopardy! yesterday saw host Alex Trebek, who died on Nov. 8 from the disease, on the quiz show in a pretaped episode. To mark the day, Trebek was dressed in purple tie. His widow Jean ...
- Alex Trebek marks World Pancreatic Cancer Day in pre-recorded video messageon November 20, 2020 at 12:30 pm
At the beginning of Thursday's episode of the game show, which was pre-taped, Trebek shared a message in honor of World Pancreatic Cancer Day.
- After COVID, Tennessee Rep Gets Pancreatic Cancer Diagnosison November 20, 2020 at 9:46 am
A Tennessee state lawmaker who was hospitalized with COVID-19 in August has been diagnosed with pancreatic cancer.
- Alex Trebek spreads awareness about 'terrible' pancreatic cancer on pre-recorded 'Jeopardy!'on November 20, 2020 at 8:33 am
In honor of World Pancreatic Cancer Day, "Jeopardy!" aired a pre-recorded show featuring Alex Trebek's touching message about pancreatic cancer.
- The University of Verona and IntraOp® Announce PancFORT Trial for Pancreatic Canceron November 20, 2020 at 3:41 am
IntraOp Medical Corporation and the University of Verona in Italy announced today the enrollment of the first patient in the PancFORT Trial: A phase II study of primary chemotherapy, stereotactic body ...
- ‘Jeopardy!' Airs Episode With Late Alex Trebek Honoring World Pancreatic Cancer Dayon November 20, 2020 at 2:38 am
The late television host Alex Trebek posthumously paid tribute to World Pancreatic Cancer Day at the beginning of Thursday’s episode of “Jeopardy!” ...
- Pancreatic Cancer Collective Announces New PSA Campaign With Keesha Sharp To Raise Awareness About Pancreatic Cancer Clinical Trialson November 20, 2020 at 1:23 am
The Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation and Stand Up To Cancer (SU2C), announced today the launch of a new public service announcement (PSA) campaign, in ...
via Bing News